Press release

Ipsen announces its corporate agenda for 2011

Paris (France), 23 December 2010 - Ipsen (Euronext: IPN; ADR: IPSEY) announces today its corporate agenda* for 2011:

2 February 2011: Full year 2010 sales
2 March 2011: Full year 2010 results
3 May 2011: First quarter 2011 sales
27 May 2011: General shareholders’ meeting
6 June 2011: Payment of 2010 dividend **
30 August 2011: First half 2011 sales & results
27 October 2011: First nine months 2011 sales

* This financial calendar is for indicative purposes only and the Group could change its publication dates should it deem it necessary.
** Pending approval of the Board of directors (1st March 2011) and of the General shareholders’ meeting (27 May 2011)

About Ipsen
Ipsen is a global biopharmaceutical group, with sales exceeding 1 billion euros in 2009. The Group has total worldwide staff of more than 4,400 employees, of which nearly 900 contribute to the discovery and development of innovative drugs for patient care. Ipsen's development strategy is based on fast growing specialty care drugs in oncology, endocrinology, neurology and hematology, and on primary care drugs. This strategy is supported by an active policy of partnerships. Ipsen’s research & development (R&D) centers and its peptide & protein engineering platform give the Group a strong competitive edge. In 2009, R&D expenditure totaled close to €200 million, representing nearly 20% of Group sales. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit our website at www.ipsen.com.

For further information:
Media
Didier Véron
Director, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
E-mail: didier.veron@ipsen.com

Financial Community
Pierre Kemula
Investor Relations Officer
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
E-mail: pierre.kemula@ipsen.com